Moleculin Biotech Inc MBRX
News
Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies
Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
Moleculin Announces Reverse Stock Split
Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
